NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team is scheduled to present on Tuesday, April 8, 2025, at 3:00 PM ET (12:00 PM PT).
The presentation will be available through a live webcast, and investors will have the opportunity to participate in one-on-one meetings with management during the conference. For those unable to attend live, a replay of the webcast will remain accessible for 90 days following the presentation in the Events section of NeuroPace's Investor website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NPCE gained 4.86%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025. Management will also host investor meetings during the conference.
The presentation will be accessible via live webcast here. A webcast replay will be available for 90 days following the presentation in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When is NeuroPace (NPCE) presenting at the Needham Healthcare Conference 2025?
How long will the NPCE Needham Conference presentation replay be available?
Where can investors access NeuroPace's (NPCE) Needham Conference presentation?
Will NPCE management be available for investor meetings at the Needham Conference?
